patients. The inevitable result is that the normal screening process is undermined, and a more extreme informal cut off point is used instead. A secondary effect is that too many of the children who are referred have unnecessary investigations, usually blood tests for growth disorders.
The 1990 British growth reference has addressed this problem by introducing an extra centile at the 4 per 1000 level. The chart guidelines state that any child whose height falls below it should be referred. Since the false positive rate is so low at this level it is reasonable to hope that such children will indeed be referred.
The sensitivity of screening programmes based on cut off points between the 3rd and the 0·4th centile has been investigated in several large studies, but the findings are hard to interpret. In each study new cases were identified from among the children falling below the cut off point, but the numbers of true cases -that is, including those above the cut off, were not known. The prevalence of all organic disease in children below the cut off point was 2 to 4 per 1000, while the proportion of new cases fell with increasing age.
There is further uncertainty about the correct denominator for calculating sensitivity. In diseases like asthma where growth faltering occurs in only a proportion of cases, should such children be counted as cases or not? Taking it a stage further, should short children who are otherwise normal be viewed as cases, on the grounds that short stature leads to psychosocial disadvantage?
Screening for poor growth as opposed to small stature or light weight is even less well documented. Height velocity is a notoriously variable measurement, even over periods of a year or more, due in part to poor measurement technique. Calculating the specificity of screening based on height velocity is not straightforward, and requires knowledge of the correlation between heights at different ages. Without this information, and a cut off to keep the false positive rate realistically low, sensitivity is impossible to calculate.
Growth monitoring is widely accepted as being useful up to school entry, even though the quantitative evidence to justify this is hard to assemble, for the reasons given above. However, there is currently considerable debate about the efficacy of continuing growth monitoring past school entry, and a large study is needed to quantify the sensitivity, specificity and positive predictive value of different screening strategies in the primary school years. Without this information an informed decision cannot be made.
Screening for growth is like any other form of screeningan outcome measure is identified that will act as a marker for the disease process, its cut off is chosen, then subjects presenting whose measurements lie beyond the cut off point are referred for further investigation.
The most effective outcome measures to identify growth disorders are height and to a lesser extent weight, measured either on a single occasion or repeatedly. One difficulty is that the term "growth disorder" is not a single clearly defined entity -very many organic conditions cause growth faltering either directly or indirectly. Small stature, for example, is often the presenting symptom for growth hormone deficiency, coeliac disease, inflammatory bowel disease, hypothyroidism, and syndromes such as Turner, Silver-Russell or Noonan. Low weight, or more likely weight loss, is a common feature of bowel disease, renal disease and many cancers. If the scope for screening is extended to include the developing world then malnutrition is another important -perhaps the most important -disease to screen for. This heterogeneity in the diagnosis makes quantification of the screening process more difficult than if there were a single outcome.
Height screening has a long history. Setting aside the screening of European army conscripts, which is known to have occurred since the 18th century, children have been screened for height and weight since the 1950s when the first growth charts were produced. This highlights a second difficulty with height and weight as outcome measures -they change dramatically with age. The choice of cut off point is inevitably bound up with the question of how to quantify these age changes -that is, how the growth chart should be constructed.
The earliest growth charts were derived entirely by hand, both in terms of the calculations and the chart drawing. For this reason the sample sizes were modest, and there were insufficient numbers to calculate centiles beyond the 3rd and 97th. If the data had been summarised in terms of the mean and standard deviation at each age then more extreme centiles could have been calculated. Yet this did not happen, and the idea of using the 3rd centile as a cut off point for short stature became ingrained. In fact the American 1977 reference actually adopted the 5th rather than the 3rd centile, and this has become a regular alternative to the 3rd.
Cut off points based on the 3rd or 5th centile have their false positive rates predetermined, as 3% of the normal population lie below the 3rd centile and 5% below the 5th (assuming that the chart is appropriate for the population). False positive rates of this magnitude pose major problems for any screening programme, as the secondary referral centres do not have the resources to handle such numbers of 
